- Home
- REE vs KTTA Comparison
REE vs KTTA Comparison
Compare REE & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REE | KTTA |
|---|---|---|
| Founded | 2011 | 2020 |
| Country | Israel | United States |
| Employees | N/A | 4 |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1M | 18.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | REE | KTTA |
|---|---|---|
| Price | $0.53 | $0.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $8.50 | $3.00 |
| AVG Volume (30 Days) | 45.9K | ★ 100.6K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $327.73 | N/A |
| Revenue Next Year | $36,888.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $0.28 |
| 52 Week High | $3.76 | $2.34 |
Technical Indicators
Market Signals| Indicator | REE | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 48.56 | 45.01 |
| Support Level | $0.53 | $0.67 |
| Resistance Level | $0.74 | $0.88 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 46.94 | 29.69 |
Price Performance
Historical ComparisonAbout REE REE Automotive Ltd.
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).